Table 2.
Details of Major Bleeding Episodes
| Patient | Age | Sex | Medication Dose Appropriate (Y/N) |
Site of Bleeding |
Platelet count at the time of bleeding |
Concomitant anti-platelet therapy |
GFR at initiation of DOAC |
GFR at the time of bleed |
Anticoagulation (Continued / Discontinued) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 84 | M | Rivaroxaban 20 mg daily (Y) |
Thalamus | 200 | N | 90 | 84 | Discontinued |
| 2 | 90 | M | Rivaroxaban 10 mg daily (N) |
GIB | 218 | N | 72 | 33 | Switched to Coumadin |
| 3 | 83 | F | Rivaroxaban 20 mg daily (Y) |
GIB | 168 | Y | 87 | 71 | Discontinued |
| 4 | 77 | F | Dabigatran 75 mg bid (Y) |
GIB | 283 | Y | 57 | 31 | Switched to rivaroxaban |
| 5 | 77 | F | Rivaroxaban 15mg daily (Y) |
Fall and hip hematoma |
264 | N | 61 | 27 | Discontinued |
GIB- gastrointestinal bleeding